Medscape: New drug reduces tics in Tourette syndrome patients without major side effects
A new study shows that an investigational drug helps reduce tics and is safe for children with Tourette syndrome (TS).
TS, a neurological condition that causes sudden repetitive involuntary muscle movements and sounds known as tics, typically develops in childhood and worsens during adolescence.
Donald Gilbert, MD, study investigator, professor of pediatrics in the University of Cincinnati College of Medicine and a pediatric movement disorders and TS specialist at Cincinnati Children's Hospital Medical Center, told Medscape the study results seem to indicate that "help is on the way" for patients looking for an effective treatment for TS without side effects like weight gain, anxiety or depression.
"There may be a drug available with a new mechanism of action that is effective to suppress tics without causing weight gain or unwanted neuropsychiatric side effects," Gilbert said.
The study findings will be formally presented at the American Academy of Neurology 2022 annual meeting in April.
Featured photo at top courtesy of Pixabay.
Related Stories
Pocket-sized population threat
June 10, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.